Matches 1 - 50 out of 136 1 2 3 >


Match Document Document Title
US20150086580 RATIONAL VACCINE DESIGN FOR HEPATITIS C VIRUS  
Compositions and methods are provided relating to HCV E2 protein and modifications thereto which enhance the immunogenicity of the protein for vaccine development with respect to the generation of...
US20150017197 HCV VACCINES AND METHODS FOR USING THE SAME  
Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a/1b NS3 and NS4A. Pharmaceutical...
US20120034256 HCV VACCINES AND METHODS FOR USING THE SAME  
Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1 a/1 b NS3 and NS4A. Pharmaceutical...
US20150166612 Vaccines And Methods For Using The Same  
Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and...
US20110091495 HCV E2 CONSTRUCT COMPOSITIONS AND METHODS  
A construct comprising the ectodomain of the Hepatitis C Virus (HCV) E2 sequence and a mammalian expression system therefor is disclosed. The construct comprises a CMV promoter, prolactin signal...
US20120301494 PROTEOLYSIS-RESISTANT CAPSID OF CHIMERIC HEPATITIS E VIRUS AS AN ORAL DELIVERY VECTOR  
This invention provides a peptide/nucleic acid composition for oral/mucosal, dual-modal activation of immune protection systems.
US20130101612 VACCINE FOR ENVELOPED VIRUSES  
The present invention provides a recombinant viral surface antigenic protein with enhanced stability. The present invention also provides a vaccine composition against enveloped viruses.
US20140286984 Compositions and Methods for the Treatment or Prevention of Hepatitis B Virus Infection  
Disclosed are yeast-based immunotherapeutic compositions, hepatitis B virus (HBV) antigens, and fusion proteins for the treatment and/or prevention of HBV infection and symptoms thereof, as well...
US20130243805 Compositions and Methods for the Treatment or Prevention of Hepatitis B Virus Infection  
Disclosed are yeast-based immunotherapeutic compositions, hepatitis B virus (HBV) antigens, and fusion proteins for the treatment and/or prevention of HBV infection and symptoms thereof, as well...
US20140193362 YEAST-BASED COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF HEPATITIS DELTA VIRUS INFECTION  
Disclosed are immunotherapeutic compositions and methods for preventing and/or treating hepatitis delta virus (HDV) infection, including yeast-based HDV immunotherapeutic compositions and methods...
US20050202036 Alternate reading frame polypeptides drived from hepatitis C and methods of their use  
Novel hepatitis C virus (HCV) polypeptides are provided which are not encoded by the standard HCV open reading frame. These alternate reading frame polypeptides are useful, inter alia, in vaccine...
US20120100170 COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATITIS C  
The present invention provides compositions and methods for delivery of one or more hepatitis C virus (HCV) antigens using a bacterium recombinantly encoding and expressing such antigens. In...
US20130171182 INFLUENZA VACCINE  
The invention provides a protein comprising a first and a second copy of hepatitis B core antigen (HBcAg) in tandem, in which one or both of the copies of HBcAg comprises influenza virus A surface...
US20110300170 HCV VACCINES  
Disclosed are methods and compositions for inducing immune responses against Hepatatis C virus (HCV). The compositions comprise one or more epitope from a hotspot epitope. In certain embodiments,...
US20130209395 NUCLEIC ACID MOLECULE ENCODING HEPATITIS B VIRUS CORE PROTEIN AND SURFACE ANTIGEN PROTEIN AND VACCINE COMPRISING THE SAME  
Provided herein are nucleic acid sequences encoding hepatitis B virus (HBV) core proteins, surface antigen proteins, fragments and combinations thereof as well as genetic constructs/vectors and...
US20130337001 Immunogenic composition for treatment of hepatitis C, a method for preparing the composition and use thereof for treating hepatitis C  
This disclosure provides an immunogenic composition comprising an amount of isolated dendritic cells comprising at least one fragment of a hepatitis C protein selected from the group consisting of...
US20130315945 YEAST-BASED VACCINES AS IMMUNOTHERAPY  
Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for...
US20130071420 YEAST-BASED VACCINES AS IMMUNOTHERAPY  
Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for...
US20130004529 VACCINES AND METHODS FOR USING THE SAME  
Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those...
US20120093849 Agents for Treatment of HCV and Methods of Use  
An amphipathic helix at the approximate N-terminus of Hepatitis C virus (HCV) nonstructural proteins mediates the association of these proteins with cytoplasmic membranes in infected cells. This...
US20140220063 VACCINE COMPOSITION  
The invention provides a vaccine composition containing an antigen for inducing cellular immunity, comprising at least one first cellular immunity induction promoter.
US20150252084 COMPOSITIONS AND METHODS THAT ENHANCE AN IMMUNE RESPONSE  
Disclosed herein are isolated nucleic acids, compositions of isolated nucleic acids, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune...
US20120121713 CHIMERIC THERAPEUTICS, COMPOSITIONS, AND METHODS FOR USING SAME  
Chimeric therapeutics are disclosed that include a modified viral core protein comprising at least one mutation or modification in an immunogenic epitope and a therapeutic agent. The therapeutic...
US20140286985 SIMPLE VACCINES FROM DNA LAUNCHED SUICIDAL FLAVIVIRUSES  
Immunogenic compositions relating to DNA launched suicidal flaviviruses and methods of administering the same are described herein.
US20150110828 YEAST-BASED THERAPEUTIC FOR CHRONIC HEPATITIS B INFECTION  
Disclosed are yeast-based immunotherapeutic compositions, hepatitis B virus (HBV) antigens, and fusion proteins for the treatment and/or prevention of HBV infection and symptoms thereof, as well...
US20140065182 YEAST-BASED THERAPEUTIC FOR CHRONIC HEPATITIS B INFECTION  
Disclosed are yeast-based immunotherapeutic compositions, hepatitis B virus (HBV) antigens, and fusion proteins for the treatment and/or prevention of HBV infection and symptoms thereof, as well...
US20110256098 IMMUNOTHERAPY FOR CHRONIC HEPATITIS C VIRUS INFECTION  
Disclosed are uses of immunotherapeutic compositions in combination with Standard of Care (SOC), or interferon therapy combined with anti-viral therapy, for the improved treatment of chronic...
US20150140103 VACCINE  
The present invention relates to a nucleic acid for vaccine that has undergone codon optimization for expression in Bombyx mori, a vector comprising the nucleic acid, Bombyx mori comprising the...
US20140112923 EPITOPE AND ITS USE OF HEPATITIS B VIRUS SURFACE ANTIGEN  
Disclosed are an epitope specific to hepatitis B virus (HBV) and use thereof. The disclosed epitope is a conservative position on which mutagenesis does not occur and, therefore, a composition...
US20130071422 ADJUVANTED VACCINES FOR SEROGROUP B MENINGOCOCCUS  
An immunogenic composition comprises (i) an immuno stimulatory oligonucleotide and a polycationic polymer, wherein the oligonucleotide and the polymer ideally associate with each other to form a...
US20120070456 POLYPEPTIDE CARRIER PROTEIN  
The invention relates to polypeptide carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are useful as components...
US20140348866 GB VIRUS C (HEPATITIS G VIRUS) FOR THE TREATMENT OF HIV  
GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or...
US20130071421 TURKEY VIRAL HEPATITIS VIRUS AND USES THEREOF  
Isolated a Turkey Viral Hepatitis picomavirus-like viruses associated with Turkey viral hepatitis, and isolated nucleic acid sequences and polypeptides are disclosed. Antibodies against antigens...
US20150152154 TUMOR VACCINATION INVOLVING A HUMORAL IMMUNE RESPONSE AGAINST SELF-PROTEINS  
The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an...
US20140302082 NUCLEIC ACID CONSTRUCT COMPRISING NUCLEIC ACID DERIVED FROM GENOME OF HEPATITIS C VIRUS OF GENOTYPE 1B, HEPATITIS C VIRUS GENOME-REPLICATING CELLS TRANSFECTED WITH THE SAME, AND METHOD FOR PRODUCING INFECTIOUS HEPATITIS C VIRUS PARTICLES  
A subgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and a fullgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and...
US20140120127 RECOMBINANT HCV E2 GLYCOPROTEIN  
The invention provides modified hepatitis C virus (HCV) E2 glycoproteins comprising the HCV-E2 receptor-binding domain (RBD) including the HVR1, HVR2 and igVR variable regions wherein in at least...
US20110177110 COMPOSITIONS COMPRISING CATIONIC MICROPARTICLES AND HCV E1E2 DNA AND METHODS OF USE THEREOF  
Immunogenic HCV E1E2809 DNA compositions and methods of using the same are described. The compositions comprise HCV E1E2809 DNA adsorbed to cationic microparticles, such as...
US20100047231 Immuno-Stimulant Combination for Prophylaxis and Treatment of Hepatitis C  
The present invention relates to an immuno-stimulant combination for prophylaxis and treatment of hepatitis C, characterised in that it comprises: a TLR3 agonist, a CD40 agonist and the NS3...
US20090258033 HCV E1E2 vaccine compositions  
HCV E1E2 compositions comprising E1E2 antigens, submicron oil-in-water emulsions and/or immunostimulatory nucleic acid sequences are described. The compositions can be used in methods of...
US20120308594 HCV CLADE AND PROTOTYPE SEQUENCES THEREOF  
The current invention relates to a previously unrecognized clade of HCV genotypes as well as to diagnostic, prophylactic and therapeutic applications of nucleic acids, proteins, and antibodies to...
US20120189648 INFECTIOUS HEPATITIS C VIRUSES OF GENOTYPE 3A AND 4A AND USES THEREOF  
The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, invention provides...
US20140199338 VACCINES FOR PROTECTION FROM AND TREATMENT OF ALZHEIMER'S DISEASE  
Disclosed herein are DNA-based vaccines against amyloid β peptide for use in treating and alleviating Alzheimer's Disease and related conditions. A DNA construct comprising DNA encoding one or...
US20090110685 Treatment and prevention of viral infections  
Disclosed is polynucleotide encoding a polypeptide comprising an antibody binding site, the polypeptide being able to bind to HCV E2 samples representative of each of HCV genotypes 1-6, as well as...
US20100074916 AVIAN INFLUENZA VACCINE  
H5 hemagglutinin (HA) polypeptides are provided that are adapted to humans through mutations that change receptor specificity in the H1 serotype, and related polynucleotides, methods,...
US20060246089 Immunogen for preparation of therapeutic vaccines or drugs for treatment of hepatitis b and the producing method and use thereof  
The present invention relates to immunogens for treatment of hepatitis B and their preparation and use, and to vaccines or medicaments comprising said immunogens for treatment of hepatitis B and...
US20110274705 METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF T CELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS  
The present invention is directed to novel compositions that cause effective redirection of class I-immunity to Tc1 effectors, that take advantage of the unexpected loading of MHC I by peptide...
US20050025780 Hepatitis b virus surface antigen as a mucosal immunostimulator and the resulting formulations  
The invention relates to a mucosal surface antigen which is used to promote and increase in the immune response against co-administered antigens in the formulations out line in the invention. Said...
US20090010932 GB VIRUS C (HEPATITIS G VIRUS) FOR THE TREATMENT OF HIV  
GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or...
US20060171956 Sphingoid polyalkylamine conjugates for hepatitis B virus vaccination  
The present invention concerns the use of a sphingoid-polyalkylamine conjugate as a capturing agent of biologically active molecules, such as antigens. In a particular embodiment, the...
US20070178115 Immunization of avians by administration of non-replicating vectored vaccines  
The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to recombinant human adenovirus vectors for delivery of avian...

Matches 1 - 50 out of 136 1 2 3 >